Security key
74365A309
Protalix BioTherapeutics, Inc. - Common Stock (PLX)
CUSIP: 74365A309
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 16,863,462
- Total 13F value
- $36,572,629
- Share change
- +1,951,572
- Put/Call ratio
- 52%
- SEC-reported price per share
- $2.17
- Number of holders
- 100
- Value change
- +$4,420,350
- Number of buys
- 52
- Number of sells
- 29
- Shares outstanding
- 80,610,558
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
100
Top holders
10
PLX full security history
Ownership snapshot
Full 13F holder table
Protalix BioTherapeutics, Inc. SEC filings
Protalix BioTherapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MAK Capital Fund LP
Disclosed value leader
MAK Capital Fund LP
Comparable rows
15/15
Latest evidence
24 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 4.5%
13D/G row: MAK Capital Fund LP
Showing 1-6 of 15 holder rows.
Quick read
MAK Capital Fund LP leads the comparable SEC ownership view at 4.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MAK Capital Fund LP's linked filing trail.
Comparable ownership
Top 5
MAK Capital Fund LP
4.5%
Gilad Mamlok
0%
BlackRock, Inc.
4.5%
Opaleye Management Inc.
3.1%
RENAISSANCE TECHNOLOGIES LLC
1.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MAK Capital Fund LP |
13D/G
|
4.5%
|
$11,355,147
3,616,289 shares
|
-$3,244,593 | 24 Mar 2026 |
| Gilad Mamlok |
3/4/5
Sr. VP and CFO
|
0%
|
$7,770
3,631 shares
|
— | 24 Aug 2025 |
| BlackRock, Inc. |
13F
Company
|
4.5%
|
$6,564,791
3,647,106 shares
|
— | 31 Dec 2025 |
| Opaleye Management Inc. |
13F
Company
|
3.1%
|
$4,460,717
2,478,176 shares
|
— | 31 Dec 2025 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
1.6%
|
$2,273,940
1,263,300 shares
|
— | 31 Dec 2025 |
| NORTHERN TRUST CORP |
13F
Company
|
1.1%
|
$1,558,274
865,708 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
100
Shares
16,863,462
Rows available
100
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
100
Q1 2026 holders
100
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|